Aβ-binding molecules: Possible application as imaging probes and as anti-aggregation agents

Science in China, Series B: Chemistry

Volumn 51, Issue 9, 2008, Pages 801-807

  Duan, XinHong ^a,b   Liu, BoLi ^a  

^a BEIJING NORMAL UNIVERSITY   (China)

^b BEIJING FORESTRY UNIVERSITY   (China)

Author keywords

A binding; A inhibitor; Bifunctional candidate; Core structure; Hydrophobic and aromatic interaction

Indexed keywords

AGGLOMERATION; ARSENIC COMPOUNDS; AZO DYES; BINDING ENERGY; BIOCHEMISTRY; CHEMOTHERAPY; CHLORINE COMPOUNDS; DRUG DELIVERY; DRUG DOSAGE; HEALTH; MOLECULES; OLIGOMERS; POLYMERS;

ALZHEIMER'S DISEASE; BIFUNCTIONAL CANDIDATE; BINDING MOLECULES; CONGO RED; CORE STRUCTURE; CORE STRUCTURES; EARLY DIAGNOSIS; HYDROPHOBIC AND AROMATIC INTERACTION; IMAGING PROBES; IN VIVO STUDIES; NON-INVASIVE IMAGING; PROBE MOLECULES; SMALL-MOLECULE INHIBITORS; THIOFLAVIN T; TREATMENT STRATEGIES;

BINDING SITES;

EID: 49749097494     PISSN: 10069291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11426-008-0075-7     Document Type: Article

References (58)

1. Selkoe D J. The origins of Alzheimer disease: A is for amyloid. JAMA, 2000, 283: 1615-1617
2. Kang J, Lemaire H G, Unterbeck A, Salbaum J M, Masters C L, Grzeschik K H, Multhaup G, Beyreuthe K, Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature, 1987, 325: 733-736
3. Harper J D, Lansbury P T Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem, 1997, 66: 385-407
4. Yankner B A, Duffy L K, Kirschner D A. Neurotrophic and neurotoxic effects of amyloid beta protein: Reversal by tachykinin neuropeptides. Science, 1990, 250: 279-282
5. Harkany T, Abraham I, Konya C, Nyakas C, Zarandi M, Penke B, Luiten P G. Mechanisms of beta-amyloid neurotoxicity: Perspectives of pharmacotherapy. Rev Neurosci, 2000, 11: 329-382
6. Walsh D M, Klyubin I, Fadeeva J V, Cullen W K, Anwyl R, Wolfe M S, Rowan M J, Selkoe D J. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 2002, 416: 535-539
7. Gong Y S, Chang L, Viola K L, Lacor P N, Lambert M P, Finch C E, Krafft G A, Klein W L. Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA, 2003, 100:10417-10422
8. Tabner B J, Turnbull S, El Agnaf O M, Allsop D. Formation of hydrogen peroxide and hydroxyl radicals from Aβ and R-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radical Biol Med, 2002, 32: 1076-1083
9. Barnham K J, Masters C L, Bush A I. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov, 2004, 3: 205-214
10. Kawahara M, Kuroda J. Molecular mechanism of neurodegeneration induced by Alzheimer's beta-amyloid protein: Channel formation and disruption of calcium homeostasis. Brain Res Bull, 2000, 53: 389-397
11. McGeer E G, McGeer P L. Brain inflammation in Alzheimer disease and the therapeutic implications. Curr Pharm Design, 1999, 5: 821-836
12. Moore A H, O'Banion M K. Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. Adv Drug Delivery Rev, 2002, 54: 1627-1656
13. Barrow C J. Advances in the development of Abeta-related therapeutic strategies for Alzheimer's disease. Drug News Perspect, 2002, 15:102-109
14. Masters C L, Cappai R, Barnham K J, Villemagne V L. Molecular mechanisms for Alzheimer's disease: Implications for neuroimaging and therapeutics. J Neurochem, 2006, 97: 1700-1725
15. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol, 2004, 3: 519-527
16. Norfray J F, Provenzale J M. Alzheimer's disease: Neuropathologic findings and recent advances in imaging. Am J Roentgenol, 2004, 182:3-13
17. 11C-labelling of (E,E)-1-(30,40-dihydroxystyryl)-4-(30- methoxy-40-hydroxystyryl) benzene for PET imaging of amyloid depositsy. J Label Compd Radiopharm, 2002, 45: 647-664
18. Klunk W E, Wang Y M, Huang G F, Debnath M L, Holt D P, Mathis C A. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci, 2001, 69:1471-1484
19. Mathis C A, Wang Y, Klunk W E. Imaging β-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Design, 2004, 10: 1469-1492
20. Styren S D, Hamilton R L, Styren G C, Klunk W E. X-34, a fluorescent derivative of congo red. A novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem, 2000, 48: 1223-1232
21. Kung H F, Lee C W, Zhuang Z P, Kung M P, Hou C, Plössl K. Novel stilbenes as probes for amyloid plaques. J Am Chem Soc, 2001, 123: 12740-12741
22. Lee C W, Kung M P, Hou C, Kung H F. Dimethylamino-fluorenes: Ligands for detecting β-amyloid plaques in the brain. Nucl Med Biol, 2003, 30: 573-580
23. Zhuang Z P, Kung M P, Hou C, Plössl K, Kung H F. Biphenyls labeled with technetium 99m for imaging β-amyloid plaques in the brain. Nucl Med Biol, 2005, 32: 171-184
24. Zhuang Z P, Kung M P, Hou C, Skovronsky D M, Gur T L, Plössl K, Trojanowski J Q, Lee V M Y, Kung H F. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J. Med Chem, 2001, 44: 1905-1914
25. Zhuang Z P, Kung M P, Hou C, Plössl K, Skovronsky D, Gur T L, Trojanowski J Q, Lee V M Y, Kung H F. IBOX (2-(4′-dimethylaminophenyl)-6- iodobenzoxazole): A ligand for imaging amyloid plaques in the brain. Nucl Med Biol, 2001, 28: 887-894
26. Kung M P, Hou C, Zhuang Z P, Zhang B, Skovronsky D, Trojanowski J Q, Lee V M Y, Kung H F. IMPY: An improved thioflavin-T derivative for in vivo labeling of β-amyloid plaques. Brain Res, 2002, 956:202-210
27. Ono M, Kung M P, Hou C, Kung H F. Benzofuran derivatives as Aβ-aggregate-specific imaging agents for Alzheimer's disease. Nucl Med Biol, 2002, 29: 633-642
28. Agdeppa E D, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, Cole G M, Small G W, Huang S C, Barrio J R. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci, 2001, 21:RC189 1-5
29. Chandra R, Kung M P, Kung H F. Design, synthesis, and structure-activity relationship of novel thiophene derivatives for β-amyloid plaque imaging. Bioorg Med Chem Lett, 2006, 16: 1350-1352
30. Chandra R, Oya S, Kung M P, Hou C, Jin L W, Kung H F. New diphenylacetylenes as probes for positron emission tomographic imaging of amyloid plaques. J Med Chem, 2007, 50: 2415-2423
31. Qu W, Kung M P, Hou C, Oya S, Kung H F. Quick assembly of 1,4-diphenyltriazoles as probes targeting β-amyloid aggregates in alzheimer's disease. J Med Chem, 2007, 50: 3380-3387
32. Lockhart A, Ye L, Judd D B, Merritt A T, Lowe P N, Morgenstern J L, Hong G, Gee A D, Brown J. Evidence for the presence of three distinct binding sites for the Thioflavin T class of Alzheimer's disease PET imaging agents on β-amyloid peptide fibrils. J Biol Chem, 2005, 280: 7677-7684
33. LeVine H. Multiple ligand binding sites on Aβ(1-40) fibrils. Amyloid, 2005, 12: 5-14
34. Agdeppa E D, Kepe V, Liu J, Small G W, Huang S C, Petric A, Satyamurthy N, Barrio J R. 2-dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): Novel diagnostic and therapeutic tools in Alzheimer's disease. Mol Imaging Biol, 2003, 5: 404-417
35. Krebs M R H, Bromley E H C, Donald A M. The binding of thioflavin-T to amyloid fibrils: Localization and implications. J Struct Biol, 2005, 149: 30-37
36. Chen X J. QSAR and primary docking studies of trans-stilbene (TSB) series of imaging agents for β-amyloid plaques. J Mol Struc-Theochem, 2006, 763: 83-89
37. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: Implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem, 2003, 87: 172-181
38. Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro. J Neurosci Res, 2004, 75: 742-750
39. Yang F S, Lim G P, Begum A N. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem, 2005, 280: 5892-5901
40. Ono M, Yoshida N, Ishibashi K, Haratake M, Arano Y, Mori H, Nakayama M. Radioiodinated flavones for in vivo imaging of β-amyloid plaques in the brain. J Med Chem, 2005, 48: 7253-7260
41. Ono M, Maya Y, Haratake M, Ito K, Mori H, Nakayama M. Aurones serve as probes of β-amyloid plaques in Alzheimer's disease. Biochem Bioph Res Co, 2007, 361: 116-121
42. Ono M, Maya Y, Haratake M, Nakayama M. Synthesis and characterization of styrylchromone derivatives as β-amyloid imaging agents. Bioorg Med Chem, 2007, 15: 444-450
43. Ono M, Hori M, Haratake M, Tomiyama T, Mori H, Nakayama M. Structure-activity relationship of chalcones and related derivatives as ligands for detecting of β-amyloid plaques in the brain. Bioorg Med Chem, 2007, 15: 6388-6396
44. Ryu E K, Choe Y S, Lee K H, Choi Y, Kim B T. Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for β-Amyloid plaque imaging. J Med Chem, 2006, 49: 6111-6119
45. Lee I, Choe YS, Kim D H, Lee K H, Choi Y, Choi JY, Kim B T. Synthesis and evaluation of RS-0406 derivatives for beta-amyloid plaque and neurofibrillary tangle imaging. J Label Compd Radio Pharm, 2007, 50: S409
46. Gazit E. A possible role for π-stacking in the selfassembly of amyloid fibrils. FASEB J, 2002, 16: 77-83
47. Makin O S, Atkins E, Sikorski P, Johansson J, Serpell L C. Molecular basis for amyloid fibril formation and stability. Proc Natl Acad Sci USA, 2005, 102: 315-320
48. Tjernberg L, Callaway D, Tjernberg A, Hahne S, Lilliehook C, Terenius L, Thyberg J, Norstedt C. A molecular model of Alzheimer amyloid β-peptide fibril formation. J Biol Chem, 1999, 274: 12619-12625
49. Mage P P. Molecular simulation of the primary and secondary structures of the Aβ(1-42) peptide of Alzheimer's disease. Med Res Rev, 1998, 18: 403-430
50. Thomas T, Nadackal G T, Thomas K. Aspirin and nonsteroidal anti-inflammatory drugs inhibit amyloid-β aggregation. Neuroreport, 2001, 12: 3263-3267
51. 18F] fluoroethyl) (methyl) amino]-2napthyl}ethylidene) malononitrile. Neurosci, 2003, 117: 723-730
52. Hirohata M, Ono K, Naiki H, Yamada M. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro. Neuropharmacology, 2005, 49: 1088-1099
53. Lee V M Y. Amyloid binding ligands as Alzheimer's disease therapies. Neurobiol Aging, 2002, 23: 1039-1042
54. Stains C I, Mondal K, Ghosh I. Molecules that target beta-amyloid. ChemMedChem, 2007, 2: 1674-1692
55. Collier T L, Waterhouse R N, Kassiou M. Imaging sigma receptors:application in drug development. Curr Pharm Design, 2007, 13:51-72
56. Johannsen B, Pietzsch H J. Development of technetium-99m-based CNS receptor ligands: have there been any advances? Eur J Nucl Med, 2002, 29: 263-275
57. Zhuang Z P, Kung M P, Hou C, Ploessl K, Kung H F. Biphenyls labeled with technetium 99m for imaging β-amyloid plaques in the brain. Nucl Med Biol, 2005, 32: 171-184
58. 99mTc-BAT- phenylbenzothiazole conjugate as a potential in vivo tracer for visualization of amyloid β. Bioorg Med Chem Lett, 2007, 17: 6086-6090